Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05498103 · ClinicalTrials.gov registry record · Phase 4
Use of Methazolamide to Lower Intraocular Pressure
A Phase 4 study of Glaucoma Open-Angle, sponsored by University of Colorado, Denver.
- Active
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05498103: Active Phase 4 study of Glaucoma Open-Angle, sponsored by University of Colorado, Denver.
NCT05498103 is a Phase 4 study of Glaucoma Open-Angle that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 30 participants, below the 164-participant average among 22 other Glaucoma Open-Angle trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05498103, a Phase 4 study of Glaucoma Open-Angle, is active but no longer recruiting, sponsored by University of Colorado, Denver.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effect of methazolamide, 25 mg or 50 mg tablets once a day for a week than twice a day for a week, on lowering intraocular pressure and the safety of methazolamide.
Primary Outcome
IOP measure is measured using Goldmann Tonometry. IOP is measured in mmHg with a normal range from 12 mmHg to 22 mmHg.
Conditions Studied
Interventions
- DRUG Methazolamide 25 MG
- DRUG Methazolamide 50 MG
Study Locations (1)
Colorado
- Sue Anschutz-Rodgers Eye Center - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-02-17 |
| Est. Completion | 2024-12 |
| Phase | Phase 4 |
What the registry record for NCT05498103 still lists
NCT05498103 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 164-participant average among 22 other Glaucoma Open-Angle trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Glaucoma Open-Angle appearing as the primary indexed condition, and to 2 interventions - of which Methazolamide 25 MG is the first listed.
NCT05498103 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT05498103 about?
NCT05498103 is a clinical study titled "Use of Methazolamide to Lower Intraocular Pressure". The purpose of this study is to evaluate the effect of methazolamide, 25 mg or 50 mg tablets once a day for a week than twice a day for a week, on lowering intraocular pressure and the safety of methazolamide.
What is the current status of trial NCT05498103?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2023-02-17. Estimated completion is 2024-12.
What conditions does trial NCT05498103 study?
This clinical trial studies the following conditions: Glaucoma Open-Angle.
What interventions are being tested in trial NCT05498103?
The interventions under investigation include: Methazolamide 25 MG (DRUG), Methazolamide 50 MG (DRUG).
Who is sponsoring clinical trial NCT05498103?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05498103 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma Open-Angle
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05498103's enrollment target sits among peer trials
30 21st of 22 higher than 1 of 22 other Glaucoma Open-Angle trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma Open-Angle trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone
RECRUITING · Phase 4
-
Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 4
-
24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring
RECRUITING
-
Electrical Stimulation for Vision Neuroenhancement in Glaucoma
RECRUITING · NA
-
Electrical Stimulation for the Treatment of Optic Neuropathies
RECRUITING · NA
-
Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI